PubRank

Paul H Lange

Author PubWeight™ 66.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010 5.98
2 Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A 2011 3.54
3 NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009 2.40
4 NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010 2.31
5 Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007 2.06
6 Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004 2.04
7 Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003 1.94
8 NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw 2009 1.86
9 Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol 2010 1.86
10 Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009 1.69
11 Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 2006 1.67
12 Point: open radical prostatectomy should not be abandoned. J Natl Compr Canc Netw 2007 1.55
13 Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 2007 1.41
14 Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 2005 1.39
15 Controversies in the surgical management of renal cancer. J Natl Compr Canc Netw 2005 1.37
16 Bladder cancer. J Natl Compr Canc Netw 2009 1.32
17 Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 2008 1.32
18 Factors that predict treatment choice and satisfaction with the decision in men with localized prostate cancer. Clin Genitourin Cancer 2006 1.29
19 Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 2008 1.23
20 Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 2007 1.10
21 Newer potential biomarkers in prostate cancer. Rev Urol 2007 1.09
22 Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res 2013 1.07
23 Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004 1.06
24 Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw 2006 1.04
25 The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Prostate 2006 1.01
26 Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007 1.00
27 Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw 2015 0.98
28 The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 2007 0.95
29 Telomerase activity in disseminated prostate cancer cells. BJU Int 2006 0.95
30 Cystoprostatectomy and neobladder construction for florid cystitis glandularis. Urology 2005 0.92
31 Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007 0.92
32 Bladder cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005 0.91
33 Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 2013 0.89
34 Role of post-chemotherapy surgery in germ cell tumors. Urol Clin North Am 2007 0.89
35 Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol 2013 0.89
36 WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res 2008 0.88
37 Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010 0.85
38 Dormancy in solid tumors: implications for prostate cancer. Cancer Metastasis Rev 2013 0.84
39 Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res 2009 0.83
40 Two-year outcome of unilateral sural nerve interposition graft after radical prostatectomy. Urology 2006 0.82
41 Editorial comment. Urology 2011 0.80
42 Penile carcinoma: lessons learned from vulvar carcinoma. J Urol 2012 0.79
43 Editorial comment on "Treatment of nonretroperitoneal residual germ cell tumor masses". Urol Oncol 2005 0.78
44 Research training in urology. Nat Clin Pract Urol 2005 0.77
45 Is surgery good for advanced localised prostate cancer? It's time to find out! Eur Urol 2006 0.77
46 Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 0.76
47 Investigations of androgen suppressive agents for prostate cancer--still pertinent, still exciting. J Urol 2003 0.75
48 Editorial comment on: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2008 0.75
49 Does the who and how of surgery in bladder cancer matter? J Clin Oncol 2004 0.75
50 Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence. Am J Surg Pathol 2014 0.75
51 Editorial comment. Urology 2010 0.75
52 Urology in the 21st century: futuristic musings. Urology 2003 0.75
53 The future of urological oncology: proceduralists or continued primary physicians and leaders. J Urol 2008 0.75
54 Kidney cancer. Clinical practice guidelines. J Natl Compr Canc Netw 2005 0.75
55 Extensive palliative surgery for advanced mesothelioma of the tunica vaginalis. Urology 2003 0.75
56 The future of urologic oncology: "Proceduralists" or continued leaders? Urol Oncol 2009 0.75
57 Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. Urol Oncol 2012 0.75
58 Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 0.75
59 Testicular cancer. Clinical practice guidelines. J Natl Compr Canc Netw 2005 0.75